このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Gossamer Bio 将来の成長

Future 基準チェック /26

Gossamer Bioは、29.9%と36.7%でそれぞれ年率29.9%で利益と収益が成長すると予測される一方、EPSはgrowで40.2%年率。

主要情報

29.9%

収益成長率

36.7%

EPS成長率

Biotechs 収益成長	24.2%
収益成長率	39.6%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	24 Jun 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

NasdaqGS:GOSS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	48	-119	-14	-104	8
12/31/2025	4	-188	-99	-131	8
12/31/2024	100	-72	12	12	8
3/31/2024	N/A	-173	-158	-158	N/A
12/31/2023	N/A	-180	-159	-159	N/A
9/30/2023	N/A	-187	-174	-173	N/A
6/30/2023	N/A	-207	-176	-176	N/A
3/31/2023	N/A	-221	-187	-187	N/A
12/31/2022	N/A	-229	-188	-187	N/A
9/30/2022	N/A	-230	-180	-180	N/A
6/30/2022	N/A	-231	-186	-185	N/A
3/31/2022	N/A	-234	-184	-183	N/A
12/31/2021	N/A	-234	-191	-189	N/A
9/30/2021	N/A	-242	-192	-185	N/A
6/30/2021	N/A	-240	-195	-188	N/A
3/31/2021	N/A	-247	-205	-183	N/A
12/31/2020	N/A	-243	-201	-176	N/A
9/30/2020	N/A	-233	-205	-184	N/A
6/30/2020	N/A	-224	-197	-175	N/A
3/31/2020	N/A	-202	-178	-169	N/A
12/31/2019	N/A	-180	-151	-145	N/A
9/30/2019	N/A	-164	-130	-126	N/A
6/30/2019	N/A	-165	-119	-105	N/A
3/31/2019	N/A	-154	-108	-75	N/A
12/31/2018	N/A	-147	-72	-51	N/A
9/30/2018	N/A	-115	-53	-32	N/A
6/30/2018	N/A	-66	-27	-16	N/A
3/31/2018	N/A	-33	1	-9	N/A
12/31/2017	N/A	-7	N/A	-6	N/A

アナリストによる今後の成長予測

収入対貯蓄率: GOSS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: GOSS今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: GOSS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: GOSSの収益 ( 36.7% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: GOSSの収益 ( 36.7% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: GOSSの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Gossamer Bio 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased by 12% to US$6.42

Price target increased by 15% to US$6.09

Price target decreased by 13% to US$5.18

Price target decreased by 7.9% to US$5.85

Price target decreased by 7.2% to US$7.05

Price target increased by 14% to US$8.20

Recent updates

Price target increased by 12% to US$6.42

COO & CFO recently bought US$59k worth of stock

Gossamer Bio, Inc. Receives A Written Notice from the Staff Regarding Minimum Bid Price Requirement

Gossamer Bio, Inc., Annual General Meeting, Jun 06, 2024

Gossamer Bio Announces Board of Directors Appointments

Price target increased by 15% to US$6.09

Gossamer Bio Inc. Appoints Bob Smith as Chief Commercial Officer

Gossamer Bio, Inc. Appoints John Quisel to Its Board of Directors

Gossamer Bio, Inc. Appoints John Quisel to Its Board of Directors

COO & CFO recently bought US$113k worth of stock

Gossamer Bio Receives Non-Compliance Notice from Nasdaq

Gossamer Bio Receives Non-Compliance Notice from Nasdaq

Gossamer Bio, Inc. Announces Resignation of Kristina Burow from the Board of Directors

Price target decreased by 13% to US$5.18

Price target decreased by 7.9% to US$5.85

Gossamer Bio, Inc. announced that it has received $211.849524 million in funding from a group of investors

New major risk - Shareholder dilution

New major risk - Share price stability

Price target decreased by 7.2% to US$7.05

Price target increased by 14% to US$8.20

Gossamer Bio, Inc., Annual General Meeting, Jun 08, 2023

COO & CFO recently bought US$56k worth of stock

Co-Founder recently bought US$1.0m worth of stock

Price target decreased to US$13.00

Gossamer Bio, Inc. Announces Seralutinib Meets Primary Endpoint in Phase 2 Torrey Study in PAH

Insufficient new directors

Chief Scientific Officer recently sold US$59k worth of stock

Peaking Back In On Gossamer Bio

Price target increased to US$18.64

Price target increased to US$18.10

Price target increased to US$17.60

Gossamer Bio, Inc. announced that it has received $120.041922 million in funding from a group of investors

Gossamer Bio, Inc. announced that it expects to receive $120.041922 million in funding from a group of investors

Gossamer Bio to raise $120M in a private equity placement

Chief Scientific Officer recently sold US$73k worth of stock

Health Check: How Prudently Does Gossamer Bio (NASDAQ:GOSS) Use Debt?

Price target decreased to US$15.80

Insufficient new directors

Gossamer Bio, Inc. Announces Topline Results from its Phase 2 SHIFT-UC Study Clinical Trial Studying GB004 in Patients

Co-Founder recently sold US$170k worth of stock

Insider recently sold US$52k worth of stock

Insider recently sold US$52k worth of stock

Insider recently sold US$52k worth of stock

Gossamer Bio, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Gossamer Bio (NASDAQ:GOSS) Has Debt But No Earnings; Should You Worry?

Price target increased to US$21.25

Insufficient new directors

Price target increased to US$19.50

Is Gossamer Bio (NASDAQ:GOSS) A Risky Investment?

Price target decreased to US$19.00

Gossamer Bio, Inc.(NasdaqGS:GOSS) dropped from Russell 2500 Growth Index

Chief Scientific Officer has left the company

Chief Scientific Officer recently sold US$52k worth of stock

Chief Scientific Officer recently sold US$52k worth of stock

Gossamer Bio, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Need To Know: Gossamer Bio, Inc. (NASDAQ:GOSS) Insiders Have Been Buying Shares

Gossamer Bio, Inc. Announces Executive Changes

Gossamer Bio (GOSS) Investor Presentation - Slideshow

Gossamer Bio Announces Appointment of Faheem Hasnain as Chief Executive Officer

Gossamer Bio, Inc. Provides Clinical-Stage Product Candidate Updates

Gossamer Bio, Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: US$8.93

Co-Founder & Chairman recently bought US$1m worth of stock

Gossamer Bio, Inc. Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis

Price target lowered to US$26.13

New 90-day low: US$10.09

Gossamer Bio Announces Presentation of GB004 Phase 1b Clinical Data at United European Gastroenterology Virtual Week 2020 and Additional Program Updates

New 90-day low: US$11.30

業績と収益の成長予測